Official Title
Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
Brief Summary

COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.

Detailed Description

Coronavirus disease 2019 (COVID-19) pandemic with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection has become a global challenge. Though most cases of
COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more
susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status.
The spectrum of disease and factors that influence the disease course in COVID-19 cases with
liver cirrhosis are incompletely defined. This muilticentre observational study
(COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors
associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.

Completed
COVID-19
Liver Cirrhosis
Eligibility Criteria

Inclusion Criteria:

- 1) Aged 18 or above;

- 2) Laboratory-confirmed COVID-19 infection;

- 3) Pre-existing liver cirrhosis based on liver biopsy or clinical findings.

Exclusion Criteria:

- 1) Pregnancy or unknown pregnancy status.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
China
Locations

Dalian Sixth People's Hospital
Dalian, China

Minda Hospital Affiliated to Hubei University for Nationalities
Enshi, China

The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Enshi, China

The First Hospital of Lanzhou University
Lanzhou, China

The Central Hospital of Lishui City
Lishui, China

Guangxi Zhuang Autonomous Region
Nanning, China

The Sixth Peoples Hospital of Shenyang
Shenyang, China

Shenzhen Third People's Hospital
Shenzhen, China

Suizhou Hospital, Hubei University of Medicine
Suizhou, China

Tianjin Second People's Hospital
Tianjin, China

Ankang Central Hospital
Wuhan, China

Renmin Hospital of Wuhan University
Wuhan, China

Wuhan Union Hospital
Wuhan, China

Xingtai People's Hospital
Xingtai, China

The Affiliated Third Hospital of Jiangsu University
Zhenjiang, China

Hepatopancreatobiliary Surgery Institute of Gansu Province
NCT Number
Keywords
Covid-19
Liver cirrhosis
clinical outcome
MeSH Terms
COVID-19
Liver Cirrhosis
Fibrosis